Status:

COMPLETED

Antiviral Efficacy, Pharmacokinetics and Safety of BILN 2061 ZW in Patients With Cirrhosis and Chronic Hepatitis C

Lead Sponsor:

Boehringer Ingelheim

Conditions:

Liver Cirrhosis

Hepatitis C, Chronic

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

Study to assess the antiviral efficacy, pharmacokinetics, and tolerability of 200 mg BILN 2061 ZW in a polyethylene glycol 400 (PEG 400: ethanol) drinking solution given orally for two days bid to pat...

Eligibility Criteria

Inclusion

  • Female or male sex, age of 18 years or older
  • Chronic Hepatitis C virus (HCV) infection
  • Liver biopsy consistent with active HCV infection obtained within the last 36 months.
  • No previous clinical evidence of decompensated cirrhosis. Present cirrhosis status consistent with grade A, according to Child-Turcotte-Pugh classification, confirmed at screening
  • No evidence of significant gastroesophageal varices (\> grade 1 or other risk factors) according to fiberoptic endoscopy performed within the last 12 months
  • No evidence of Hepatocellular carcinoma (HCC) by ultrasound performed at screening
  • Written informed consent consistent with International Committee on Harmonization (ICH) / Good Clinical Practice (GCP) and local legislation given prior to any study procedures
  • HCV of genotype I
  • HCV load greater than 50,000 copies messenger ribonucleic acid (mRNA) per ml serum at screening

Exclusion

  • Women of childbearing potential or breastfeeding women. Postmenopausal women less than 6 months after last menses, surgically sterilized or hysterectomised less than 3 months after operation or not having negative serum pregnancy test
  • Males not using an adequate form of contraception (condom, sterilization at least 6 months post operation) in case their partner is of childbearing potential (criteria see above) and is not using an adequate form of contraception (hormonal contraceptives, oral or injectable/ implantable, intra-uterine device (IUD))
  • Any other or additional plausible cause for chronic liver disease, including the presence of other viruses known or suspected to cause hepatitis
  • Evidence of gastroesophageal varices
  • Any histological evidence of hepatocytic dysplasia
  • Following serological constellations: Hepatitis B surface (HBs)-Ag positive OR anti-Hepatitis B core (HBc) positive with anti- HBs negative OR anti-HAV IgM positive OR anti-Human immunodeficiency Virus (HIV) positive
  • History of abuse of alcohol within the past twelve months
  • Planned or concurrent usage of any other pharmacological therapy at screening, including any antiviral therapy
  • Any concurrent infectious disease requiring antimicrobial treatment
  • History of malignancy (except for previously cured squamous cell or basal cell carcinoma of the skin)
  • Usage of any investigational drug within thirty (30) days prior to enrolment; or the planned usage of an investigational drug during the course of the current study
  • Known hypersensitivity to drugs
  • Inability to comply with the protocol
  • Prior or present Child´s B or C liver diseases -
  • Bilirubin - refer to following exclusion criterion
  • Prothrombin time \< 70%
  • Albumin \< 3.5 g/dl
  • Clinical evidence of ascites
  • Clinical evidence of encephalopathy
  • Clinically apparent jaundice or a total bilirubin or alkaline phosphatase exceeding 2.0 x upper limit of normal (ULN) at screening
  • ALT or AST \>= 10 x ULN at screening
  • A platelet count of less than 80.000 platelets per mm3 at screening
  • White blood cell count of less than 2,000 cells per mm3 at screening
  • AFP \> 100 ng/ml
  • Splenectomy
  • Positive test for illicit or unprescribed drugs or medications at screening. Positive test for cannabis may be allowed if the investigator assesses this result not as clinically significant
  • Patients with any clinically significant laboratory abnormalities based on the investigator's medical assessment at screening

Key Trial Info

Start Date :

September 1 2002

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

Estimated Enrollment :

10 Patients enrolled

Trial Details

Trial ID

NCT02226939

Start Date

September 1 2002

Last Update

August 27 2014

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.